Necrotizing Crescentic Glomerulonephritis in COL4A3-Associated Alport Syndrome: Dual Pathology or Novel Phenotype? (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0749; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "The patient was subsequently treated with glucocorticoids, rituximab, and avacopan. Persistent renal decline despite aggressive immunosuppression further complicates management. This case underscores the importance of genetic testing and pathology re-review in atypical crescentic GN presentations."
Cardiovascular • Genetic Disorders • Glomerulonephritis • Hypertension • Lupus Nephritis • Nephrology • Polyendocrine Metabolic Ovarian Syndrome • Renal Disease • COL4A5
|
|
Samhitha Gonuguntla; Sreedevi Koppisetti Jenigiri
|